Dr. John Cush RheumNow
3 years 11 months ago
RheumNow Rheumatology Roundup
Dr. Jack Cush and Dr. Arthur Kavanaugh discuss, dissect and deliberate the sessions and data presented at the #ACR22 meeting in Philadelphia.
https://t.co/ppe5I5upvj https://t.co/su4SOS7MAg
Dr. John Cush RheumNow
3 years 11 months ago
Monday #ACR22 Daily Recap
https://t.co/QZTag5Hyol https://t.co/rgpxI9AOHP
Dr. John Cush RheumNow
3 years 11 months ago
FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety data review reports of hypocalcemia w/ advanced CKD. Monitor Ca, use Ca & vit D supplements. Await further FDA information https://t.co/QMOtYs0eBY https://t.co/wzhIg53kCs
Dr. John Cush RheumNow
3 years 11 months ago
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at #ACR22
https://t.co/DEUykGt8pT https://t.co/sz8GRRGrPH
Dr. John Cush RheumNow
3 years 11 months ago
Do oral JAKs in atopic dermatitis cause VTE? Meta-analysis (15 RCTs, 466 993 pts) does NOT show increased risk of VTE associated with AD & JAK inhibitors (HR 0.95) w/ low VTE incidence (0.05%) w/ JAKi and (0.03%) placebo. https://t.co/mO2DHzjVJw https://t.co/aaC82UStob
Dr. John Cush RheumNow
3 years 11 months ago
Photovoice: A New Visual Research Method in Lupus
Dr. Bella Mehta ( @bella_mehta) talks with Dr. Candace Feldman about Abstract 1099: Empowering Patients with Lupus Through Their Photographs at #ACR22.
https://t.co/tPizbi16Om https://t.co/lYUXaGEerA
Catherine Sims, MD DrCassySims
3 years 11 months ago
Is toci an option in refractory PMR? #ACR22
📍double-blind RCT
💪101 pts w/GC-resistant PMR (mod. dz on pred. < 10 mg)
💉toci 8 mg/kg q4w + pred taper vs. placebo + pred taper over 24w
🌟49% in toci group stopped pred at week 24 vs. 20% in placebo
🌟AE similar b/t groups
ACR_Journals ACR_Journals
3 years 11 months ago
Just accepted in Arthritis & Rheumatology:
Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population-Based Study Over Four Decades—The Lupus Midwest Network (LUMEN)
https://t.co/StigaFb3YZ
Dr. John Cush RheumNow
3 years 11 months ago
Impact of COVID 19 on Pregnancies in Women with RMD
Dr. Cassy Sims ( @DrCassySims) discusses abstract 0950 at #ACR22.
https://t.co/qbFRV5P3eP https://t.co/cmS4n15L5e
Dr. John Cush RheumNow
3 years 11 months ago
What lifestyle factors affect TNF inhibitor efficacy in AxSpA?
Dr Chao ( @doctorRBC) discusses Abstract 1510 at #ACR22 . Abstract 1510: Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of TNF Inhibitors in AxSpA
https://t.co/h8ZniRF5rO https://t.co/SZq5bvYPzt
Dr. John Cush RheumNow
3 years 11 months ago
RA-ILD: an update
Dr. Julian Segan ( @JulianSegan) discusses Abstract #1393 and Abstract #0245 presented at #ACR22.
https://t.co/5Vk4NaWzqc https://t.co/doqhqeNgdX
Dr. John Cush RheumNow
3 years 11 months ago
Are MDA criteria created equal in PsA?
Dr. Rachel Tate ( @uptoTate ) reviews abstract #1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
Presented at #ACR22.
https://t.co/H4wPHEV8D5 https://t.co/NqXYxXRNEX
Dr. John Cush RheumNow
3 years 11 months ago
Where are we with treating Pre-Rheumatoid Arthritis?
Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0530, #1603 and #1604 shared at #ACR22.
https://t.co/zWTFMgSmvA https://t.co/DYRUI4gfNU
While have come so far from the days of our patients living on massive doses of steroids, we still have many patients who use steroids for our diseases, with increasing data for toxicity, even in low dose. As someone much smarter than me described them, steroids are our best frenemy.
Hydroxychloroquine remains the backbone of treatment for SLE, and the only drug clinically proven to decrease mortality. Optimization of usage is therefore critical in maximizing benefit and preventing harms. Hydroxychloroquine blood level testing is available in clinical practice and can help guide this management.

